Baxter Stock Falls After it Unloads Kidney Care Division in $3.8B Deal

Key TakeawaysBaxter shares slid after the company agreed to sell its kidney care division to Carlyle for $3.8 billion in cash.The company plans to use the roughly$3 billion in after-tax proceeds to reduce its debt.Carlyle's investment is being made through a partnership with Atmas Health. Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash. The deal is expected to generate roughly$3 billion ...